Shopping Cart
Remove All
Your shopping cart is currently empty
Boserolimab
Copy Product Info
😃Good
Catalog No. T80567Cas No. 2444297-08-7
Alias MK-5890
Boserolimab (MK-5890) is a humanized monoclonal antibody targeting CD27 with agonistic activity. It partially blocks the binding of soluble CD70 to CD27-expressing membranes and can be used in lung cancer research.
Boserolimab
Boserolimab
Copy Product Info😃Good
Purity: 95%
Catalog No. T80567Alias MK-5890Cas No. 2444297-08-7
Boserolimab (MK-5890) is a humanized monoclonal antibody targeting CD27 with agonistic activity. It partially blocks the binding of soluble CD70 to CD27-expressing membranes and can be used in lung cancer research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $163 | - | In Stock | |
| 5 mg | $496 | - | In Stock | |
| 10 mg | $795 | - | In Stock | |
| 25 mg | $1,180 | - | In Stock | |
| 50 mg | $1,580 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Storage & Solubility Information
| Description | Boserolimab (MK-5890) is a humanized monoclonal antibody targeting CD27 with agonistic activity. It partially blocks the binding of soluble CD70 to CD27-expressing membranes and can be used in lung cancer research. |
| In vitro | Boserolimab (0-20 µg/mL, 3 days) partially blocked binding of soluble CD70 to CD27-expressing membranes (IC50=0.24 nM), activated the NF-κB signaling pathway, promoted T cell activation, and enhanced IFNγ secretion [1]. |
| In vivo | Boserolimab (5 mg/kg, intraperitoneal injection, 3 times weekly for 3–7 doses) enhances immune responses and exhibits antitumor activity against MC38 in a mouse xenograft model [1]. |
| Synonyms | MK-5890 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | CD27 |
| Cas No. | 2444297-08-7 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Boserolimab | purchase Boserolimab | Boserolimab cost | order Boserolimab | Boserolimab in vivo | Boserolimab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.